NASDAQ:SURF - Surface Oncology Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.41 -0.07 (-1.28 %) (As of 02/18/2019 04:00 PM ET)Previous Close$5.48Today's Range$5.31 - $5.6052-Week Range$3.45 - $18.18Volume71,922 shsAverage Volume71,531 shsMarket Capitalization$149.76 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts. Receive SURF News and Ratings via Email Sign-up to receive the latest news and ratings for SURF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SURF Previous Symbol CUSIPN/A Webwww.surfaceoncology.com Phone617-714-4096Debt Debt-to-Equity RatioN/A Current Ratio6.44 Quick Ratio6.44Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.63 million Price / Sales22.59 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on Equity-5.33% Return on Assets-1.28%Miscellaneous Employees56 Outstanding Shares27,682,000Market Cap$149.76 million OptionableNot Optionable Surface Oncology (NASDAQ:SURF) Frequently Asked Questions What is Surface Oncology's stock symbol? Surface Oncology trades on the NASDAQ under the ticker symbol "SURF." How were Surface Oncology's earnings last quarter? Surface Oncology Inc (NASDAQ:SURF) announced its earnings results on Tuesday, November, 13th. The company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.06. The business earned $1.73 million during the quarter, compared to the consensus estimate of $2 million. View Surface Oncology's Earnings History. What price target have analysts set for SURF? 4 brokers have issued 12-month target prices for Surface Oncology's shares. Their predictions range from $17.00 to $26.00. On average, they expect Surface Oncology's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 306.7% from the stock's current price. View Analyst Price Targets for Surface Oncology. What is the consensus analysts' recommendation for Surface Oncology? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Surface Oncology. Has Surface Oncology been receiving favorable news coverage? Media stories about SURF stock have trended positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Surface Oncology earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the near term. Who are some of Surface Oncology's key competitors? Some companies that are related to Surface Oncology include Osiris Therapeutics (OSIR), PDL BioPharma (PDLI), Adaptimmune Therapeutics (ADAP), DBV TECHNOLOGIE/S (DBVT), Replimune Group (REPL), Agenus (AGEN), Nightstar Therapeutics (NITE), Translate Bio (TBIO), Scholar Rock (SRRK), Mesoblast (MESO), Cellular Biomedicine Group (CBMG), MeiraGTx (MGTX), Voyager Therapeutics (VYGR), CASI Pharmaceuticals (CASI) and Gamida Cell (GMDA). Who are Surface Oncology's key executives? Surface Oncology's management team includes the folowing people: Mr. Daniel S. Lynch, Exec. Chairman (Age 61)Mr. J. Jeffrey Goater, CEO, Pres, Sec. & Director (Age 44)Dr. Vito J. Palombella, Chief Scientific Officer (Age 56)Ms. Jessica Fees, Sr. VP of Fin. & Bus. OperationsDr. Scott C. Chappel, Chief Technology Officer (Age 68) When did Surface Oncology IPO? (SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO. Who are Surface Oncology's major shareholders? Surface Oncology's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.96%), Victory Capital Management Inc. (1.91%), Millennium Management LLC (1.24%), Northern Trust Corp (0.43%), Geode Capital Management LLC (0.42%) and Bank of America Corp DE (0.32%). Company insiders that own Surface Oncology stock include David S Grayzel and Lilly Ventures Fund I Llc. View Institutional Ownership Trends for Surface Oncology. Which institutional investors are selling Surface Oncology stock? SURF stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Victory Capital Management Inc.. View Insider Buying and Selling for Surface Oncology. Which institutional investors are buying Surface Oncology stock? SURF stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, Squarepoint Ops LLC, Northern Trust Corp, Geode Capital Management LLC, Alambic Investment Management L.P., Strs Ohio and Acadian Asset Management LLC. Company insiders that have bought Surface Oncology stock in the last two years include David S Grayzel and Lilly Ventures Fund I Llc. View Insider Buying and Selling for Surface Oncology. How do I buy shares of Surface Oncology? Shares of SURF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Surface Oncology's stock price today? One share of SURF stock can currently be purchased for approximately $5.41. How big of a company is Surface Oncology? Surface Oncology has a market capitalization of $149.76 million and generates $6.63 million in revenue each year. Surface Oncology employs 56 workers across the globe. What is Surface Oncology's official website? The official website for Surface Oncology is http://www.surfaceoncology.com. How can I contact Surface Oncology? Surface Oncology's mailing address is 50 HAMPSHIRE STREET 8TH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-4096 or via email at [email protected] MarketBeat Community Rating for Surface Oncology (NASDAQ SURF)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 63 (Vote Outperform)Underperform Votes: 63 (Vote Underperform)Total Votes: 126MarketBeat's community ratings are surveys of what our community members think about Surface Oncology and other stocks. Vote "Outperform" if you believe SURF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SURF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2019 by MarketBeat.com StaffFeatured Article: Why is the LIBOR significant?